Compare Procter & Gamble Co (PG) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Procter & Gamble Co vs Twist Bioscience Corp — how do they compare? Procter & Gamble Co trades at $143.47 (market cap $338.13B), while Twist Bioscience Corp trades at $125.52 (market cap $8.42B). The key difference: Procter & Gamble Co is far larger — about 40.2× Twist Bioscience Corp's market cap, and Procter & Gamble Co pays a 2.99% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| PG | TWST | |
|---|---|---|
Market Cap | $338.13B | $8.42B |
Volume | 6,423,436 | — |
Sector | Consumer Staples | Health |
52-Week High | $167.18 | $153.10 |
52-Week Low | $138.10 | $24.16 |
Enterprise Value | $363.97B | $8.35B |
Dividend Yield | 2.99% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Procter & Gamble (PG) trades at $145.59, down 0.57% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q3 2026 EPS expected at $1.89. Fundamentals show robust profitability, including a net income margin of 18.44% and ROE of 30.13%, though valuation ratios like P/E of 21.99 and P/S of 4.05 are at premiums to peers. Recent news highlights PG's dividend reliability and supply chain enhancements.
PG offers stability with consistent dividend growth and solid cash flows, but premium valuation and soft demand outlook pose near-term risks. Analyst consensus is bullish with a $161.20 price target, though technical weakness suggests potential consolidation. Key risks include economic sensitivity and competitive pressures, while institutional activity shows mixed positioning.
Twist Bioscience (TWST) trades at $128.06, up 2.68% today, but remains below the analyst consensus price target of $106.14. The stock shows mixed technical signals with bearish overall momentum but bullish moving averages. Fundamentally, the company continues to report losses with a net income margin of -31.66% despite 23% revenue growth in Q3 2026. Recent news highlights AI-driven optimism and institutional buying interest.
TWST presents a high-risk growth story with strong analyst support (79% buy ratings) but persistent profitability challenges. The stock's valuation appears stretched with P/S of 18.09 and P/B of 18.89. Key catalysts include AI drug discovery partnerships and path to EBITDA breakeven, while risks include cash burn and competitive pressures in biotech.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Procter & Gamble Co
The Procter & Gamble Company manufactures and markets consumer products in countries throughout the world. The Company provides products in the laundry and cleaning, paper, beauty care, food and beverage, and health care segments. Procter & Gamble products are sold primarily through mass merchandisers, grocery stores, membership club stores, drug stores, and neighborhood stores.
Read more on PG →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
